(Q36009272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

main subject

hepatocellular carcinoma

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yi-Hsiang Huang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

I-Cheng Lee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yi-Tzen Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yee Chao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Teh-Ia Huo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Chung-Pin Li

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Han-Chieh Lin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Fa-Yauh Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

1 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

e688

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

Prognosis of untreated hepatocellular carcinoma.

5 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Emerging targeted strategies in advanced hepatocellular carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Epidemiology of viral hepatitis and hepatocellular carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Management of hepatocellular carcinoma: An update

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

2 October 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Sorafenib in advanced hepatocellular carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Design and endpoints of clinical trials in hepatocellular carcinoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Management of hepatocellular carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

A model to predict survival in patients with end-stage liver disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4554055

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25860213

12 December 2020

inferred from PubMed ID database lookup

Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25860213

12 December 2020

inferred from PubMed ID database lookup

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25860213

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1097/MD.0000000000000688

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

release_wiibljm2nrhnvg2ivgezg6gine

5 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wiibljm2nrhnvg2ivgezg6gine

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25860213%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

25860213

1 reference